The severity of ACR was determined using the ISHLT grading system.11 When antibody-mediated rejection (AMR) was suspected, patients were assessed for the presence of anti-human leukocyte antigen antibodies and endomyocardial specimens were subjected to immunofluorescence staining to determine the presence of pericapillary C4d positivity. Patient survival was assessed from the time of transplantation until the end of the study period. following HTx was worse in patients not GPR44 receiving induction therapy. No differences were noted in survival or the incidence of rejection between the daclizumab- and basiliximab-treated groups. Induction therapy was less used in patients with infection, which was related to prior VAD support. pneumonia prophylaxis after transplantation. Atovaquone 1,500mg once daily was used in patients with sulfa allergy, persistent leukopenia, hyperkalemia, or renal dysfunction. Valganciclovir was also used for 6C12 months in all patients at risk of cytomegalovirus (CMV) disease (donor or recipient CMV seropositive). In cases where both the donor and recipient were CMV seronegative, acyclovir was given as prophylaxis against herpes simplex virus. All patients received nystatin for thrush prophylaxis for at least 6 months. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, such as pravastatin or atorvastatin, were prescribed to all patients, except for those with documented contraindications to therapy. Patients presenting with a low-grade, asymptomatic ACR episode (grade 1R/1B) were treated with an oral steroid pulse (100mg prednisone) with a rapid taper to their baseline prednisone dose. All patients with suspected or biopsy-proven ACR episodes (grade 2R) were treated with 3 g methylprednisolone i.v. over 3 days. In cases of hemodynamic compromise or severe rejection (grade 3R), rabbit anti-thymocyte ALK inhibitor 2 globulin was givenfor 7C10 days. Rejection Monitoring and Post-Transplant Outcome Analysis Following transplantation, patients underwent surveillance endomyocardial biopsies once weekly for 4 weeks, biweekly for an additional 8 weeks, monthly until 6 months after transplantation, and bimonthly until 12 months after transplantation. Thereafter, patients underwent endomyocardial biopsy at the discretion of their physician. Emergency endomyocardial biopsies were performed when warranted by the patient’s clinical condition. The severity of ACR was determined using the ISHLT grading system.11 When antibody-mediated rejection (AMR) was suspected, patients were assessed for the presence of anti-human leukocyte antigen antibodies and endomyocardial specimens were subjected to immunofluorescence staining to determine the presence of pericapillary C4d positivity. Patient survival was assessed from the time of transplantation until the end of the study period. The occurrence of ACR (Grade 2R) episodes as well as AMR within 1 year ALK inhibitor 2 after transplantation was also analyzed. In the present study, AMR was defined as the presence of C4d on endomyocardial biopsy, regardless of the presence of allograft dysfunction. Statistical Analysis Continuous data are presented as meanSD. Normality was evaluated for each variable from normal distribution plots and histograms. For data showing a bimodal distribution, such as non-Gaussian distribution or positive/negative skewness, logarithmic transformation of the variables was performed as needed to improve normality before performing statistical analyses. Variables were compared between the groups with Student’s unpaired 2-tailed t-test. Analysis of variance, with Scheffe’s F adjustment for multiple comparisons, was used to assess differences among groups. Categorical variables were compared using the Chi-squared test. P 0.05 was considered significant. Post-transplant survival of patients was compared using Kaplan-Meier methods with the log-rank test. All data were analyzed using JMP 7.0 (SAS Institute, Cary, NC, USA). Results Patient Characteristics In a11, 235 ALK inhibitor 2 adult patients were included in the analysis: 70 patients did not receive induction therapy, 98 patients received daclizumab induction therapy, and 67 received basiliximab. Patients receiving daclizumab were found to be younger (50.314.7 years) than patients receiving either no induction therapy (54.914.1 years) or basiliximab induction therapy (55.811.2 years; P=0.02). There were no significant differences in any other baseline demographics among the groups (Table 1). Table 1 Baseline Characteristics thead th align=”left”.